Quantbot Technologies LP Makes New Investment in Regeneron Pharmaceuticals, Inc. $REGN

Quantbot Technologies LP acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,460 shares of the biopharmaceutical company’s stock, valued at approximately $910,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. SHP Wealth Management acquired a new position in Regeneron Pharmaceuticals in the fourth quarter valued at $26,000. Western Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the first quarter worth about $26,000. Titan Wealth CI Ltd acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $29,000. Mowery & Schoenfeld Wealth Management LLC purchased a new position in shares of Regeneron Pharmaceuticals during the second quarter worth about $29,000. Finally, Trust Co. of Vermont purchased a new stake in Regeneron Pharmaceuticals during the 2nd quarter valued at approximately $29,000. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 2.3%

Shares of REGN opened at $814.79 on Thursday. The company has a current ratio of 3.34, a quick ratio of 2.78 and a debt-to-equity ratio of 0.06. The firm’s 50-day moving average is $709.88 and its two-hundred day moving average is $717.69. Regeneron Pharmaceuticals, Inc. has a twelve month low of $541.00 and a twelve month high of $847.00. The firm has a market capitalization of $83.89 billion, a P/E ratio of 20.14, a PEG ratio of 1.42 and a beta of 0.22.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion during the quarter, compared to the consensus estimate of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company’s revenue for the quarter was up 16.7% on a year-over-year basis. During the same period last year, the firm earned $12.81 EPS. On average, research analysts predict that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be issued a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 annualized dividend and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 9.29%.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the business’s stock in a transaction on Thursday, July 2nd. The stock was sold at an average price of $650.15, for a total transaction of $130,030.00. Following the sale, the director directly owned 17,303 shares in the company, valued at approximately $11,249,545.45. The trade was a 1.14% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $320,000.00. Following the completion of the sale, the director owned 603 shares in the company, valued at $482,400. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 1,400 shares of company stock worth $1,090,030. 6.97% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on the company. BMO Capital Markets lowered their target price on Regeneron Pharmaceuticals from $900.00 to $730.00 and set an “outperform” rating on the stock in a research note on Monday, May 18th. Citigroup upped their price target on Regeneron Pharmaceuticals from $700.00 to $740.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. HSBC decreased their price target on Regeneron Pharmaceuticals from $990.00 to $880.00 and set a “buy” rating for the company in a report on Monday, July 6th. Leerink Partners boosted their price objective on shares of Regeneron Pharmaceuticals from $641.00 to $824.00 and gave the company a “market perform” rating in a research note on Monday, August 17th. Finally, Barclays dropped their price objective on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating on the stock in a research note on Thursday, April 30th. Fifteen investment analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $800.36.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Despite the setback, Wall Street remains generally constructive on Regeneron’s long-term growth prospects, and the shares have outperformed the broader S&P 500 over the past year. The company’s latest reported quarter also showed strong execution, with revenue up 16.7% year over year and EPS substantially above consensus estimates. Regeneron Pharmaceuticals Stock Outlook: Is Wall Street Bullish or Bearish?
• Neutral Sentiment: A reported August short-interest update showed zero shares sold short, but the figures appear incomplete or erroneous because the reported change was listed as “NaN.” It therefore provides little reliable information about current trading sentiment.
• Negative Sentiment: Several law firms announced or promoted a securities class action alleging that Regeneron misled investors about the viability and prospects of the Phase 3 Fianlimab-Libtayo melanoma study, including by emphasizing earlier-stage results and practice-changing expectations. The allegations have not been proven, but the litigation adds reputational, financial, and uncertainty-related overhang. Investors who purchased shares between August 1, 2025, and May 15, 2026, are being reminded of a September 14, 2026, deadline to seek lead-plaintiff status. Regeneron Investors: September 14, 2026 Lead Plaintiff Deadline

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.